Howard Hochster, MD, shares opinion of the \

(5:51)

Dr. Howard Hochster Discusses Clinical Cancer, Gastrointestinal (GI) Oncology, and Colon Cancer

(2:23)

Howard Hochster, MD, Explains Colorectal Cancer Screening Guidelines

(1:34)

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

(32)

Howard Hochster Part 1 of 3

(43)

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC

(1:53)

Dr. Howard Hochster Discusses the Importance of Clinical Trials in Oncology

(1:49)

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

(1:34)

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

(1:30)

Howard Hochster MD, provides thoughts on potential practice changing results of the Keynote177 study

(1:16)

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

(56)

Howard Hochster, MD, on whether atezolizumab + bevacizumab regimen is a new standard in care in HCC

(4:23)

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

(1:19)

Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancers

(2:9)

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

(1:39)

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

(3:41)

Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu in GI cancers

(2:9)

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

(3:24)

Howard Hochster, MD, regarding the role of genetic testing in mCRC

(1:15)

Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer

(3:14)